| PG |
Report |
Organic sales growth |
MISS |
pred ~1.7% vs. cons 2.1% |
MEDIUM |
| PG |
Report |
Core EPS |
IN-LINE |
pred ~$1.40 vs. cons $1.41 |
MEDIUM |
| PG |
Report |
Core gross margin |
MISS |
pred ~47.8% vs. cons 48.4% |
LOW |
| PG |
Guide |
Core EPS |
LOWER |
guide midpoint ~$6.96 vs. cons $7.03 (FY2027) |
MEDIUM |
| PG |
Guide |
Organic sales growth |
UNCHANGED |
guide midpoint ~3.0% vs. cons 3.0% (FY2027) |
MEDIUM |
| PG |
Guide |
Core gross-margin change |
LOWER |
guide/commentary ~-50 bps YoY vs. cons -20 bps YoY (FY2027) |
LOW |
| PG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.4% |
— |
MEDIUM |
| PG |
Return |
5-day cumulative residual |
-3.1% (FOLLOW-THROUGH) |
FY2027 core-EPS guidance near $6.96 versus $7.03 consensus and gross-margin commentary near -50 bps versus -20 bps should trigger out-period estimate cuts; a low Q4 bar limits the initial decline, but revisions extend it through day 5. |
MEDIUM |